User:Drugs4life2018/sandbox



= WNK1 = From Wikipedia, the free encyclopedia

WNK (lysine deficient protein kinase 1), also known as WNK1, is an enzyme that is encoded by the WNK1 gene. WNK1 is serine-threonine kinase and part of the "with no lysine/K" kinase WNK family. The predominant role of WNK1 is the regulation of cation-Cl- cotransporters (CCCs) such as the sodium chloride cotransporter (NCC), basolateral Na-K-Cl symporter (NKCC1), and potassium chloride cotransporter (KCC1) located within the kidney. CCCs mediate ion homeostasis and modulate blood pressure by transporting ions in and out of the cell. WNK1 mutations as a result have been implicated in blood pressure disorders/diseases; a prime example being familial hyperkalemic hypertension (FHHt).

Contents
[[null hide] ]
 * 1Structure
 * 2Function
 * Sodium Reabsorption
 * Potassium Secretion
 * Cell Volume Regulation
 * GABA Neurons
 * 3Clinical significance
 * 4Comparative genomics
 * 5References
 * 6Further reading
 * 7External links

Structure[edit]
The WNK1 protein is composed of 2382 amino acids (molecular weight 230 kDa). The protein contains a kinase domain located within its short N-terminaldomain and a long C-terminal tail. The kinase domain has some similarity to the MEKK protein kinase family. As a member of the WNK family, the kinase's catalytic lysine residue is uniquely located in beta strand 2 of the glycine loop. In order to have kinase activity, WNK1 must autophosphorylate the serine 382 residue found in its activation loop. Further, phosphorylation at another site (Ser378) increases WNK1 activity. An autoinhibitory domain is located within the C-terminal domain along with a HQ domain that is needed for WNK1 interactions with other WNKs. The interactions between WNKs play an important role in function; WNK1 mutants that lack an HQ domain also lack kinase activity.

Function[edit]
The WNK1 gene encodes a cytoplasmic serine-threonine kinase expressed in the distal nephron. Studies have shown that WNK1 can activate multiple CCCs. WNK1 however, does not directly phosphorylate the CCCs themselves rather it phosphorylates other serine-threonine kinases: Sterile20 related proline-alanine-rich kinase (SPAK) and oxidative stress response kinase 1 (OXSR1). Phosphorylation of SPAK's T loop located in its catalytic domain will activate SPAK, which will go on to phosphorylation the CCC's N-terminaldomain. Hence, WNK1 activates CCCs indirectly as an upstream regulator of SPAK/OSR1.

Sodium Reabsorption
In the distal convoluted tubule (DCT), WNK1 is a potent activator of the NCC that results in an increase in sodium re absorption that drives an increase in blood pressure. The WNK1 mutant found in FHHt harbors a large deletion within intron 1 that causes an increase in the expression of full length WNK1. The boost in WNK1 leads to increases in NCC activation that promotes the high blood pressure/hypertension associated with FHHt. WNK1 activates the serum-and glucocorticoid-inducible protein kinase SGK1, leading to increased expression of the epithelial sodium channel (ENaC), which also promotes sodium re absorption.

Potassium Secretion
WNK1 regulates potassium channels found in the cortical collecting duct (CCD) and connecting tubule (CNT). Renal outer medullar potassium 1 (ROMK1) and large conductance calcium-activated potassium channe l (BKCa) are the two primary channels for potassium secretion. WNK1 indirectly stimulates clathrin-dependent endocytosis of ROMK1 by a potential interaction with intersectin (ITSN1); thus, kinase activity is not needed. Another possible mechanism of ROMK1 regulation is via autosomal recessive hypercholeserolemia (ACH), which is a clathrin adaptor molecule. ACH phosporylation by WNK1 promotes the translocation of ROMK1 to clathrin coated pits triggering endocytosis. WNK1 may indirectly activate BKCa by inhibiting the actions of extracellular signal–regulated kinases (ERK1 and ERK2) that lead to lysomal degradation.

Cell Volume Regulation
The NKCC1/2 cotransporters are regulated by intracellular Cl- concentration. Studies point to WNK1 as key effector that couples Cl- concentration to NKCC1/2 function. In hypertonic (high extracellular Cl- ) conditions that trigger cell shrinkage, an unknown mechanism upregulates WNK1 expression to counteract the volume loss. The increased WNK1 leads to activation of SPAK/OSR1 that activate NKCC1/2 via subsequent phosphorylation. NKCC1/2 will promote the influx of Na+, K+, and Cl- ions into the cell thereby causing the flow of water into the cell. In the reverse circumstances, where hypotonic (low extracellular Cl- ) conditions induce cell swelling, WNK1 is inhibited. Another cotransporter, KCC is inactive when phosphorylated; without activated WNK1, KCC does not undergo phosphorylation and can activate. The cotransporter will promote the efflux of K+ and Cl- ions and cause the flow of water out of the cell to combat swelling.

WNK1 in the Brain
In the mature brain, the GABA neurotransmitter represents the major inhibitory signal used in neuronal signaling. GABA activates the GABAA receptor which is a Cl- ion channel. Cl- ions will enter the neuron causing hyperpolarization and inhibition of signaling. During brain development however, GABAA activation will allow Cl- ions to leave the neuron causing the neuron to depolarize. Thus, GABA is an excitatory neurotransmitter during development. WNK1 has been implicated in the developmental switch from excitatory to inhibitory GABA signaling via interaction with NKCC1 and KCCs. WNK1 phosphorylates SPAK/OSR1 which then phosphorylates KCC2 inhibiting the flow of Cl- ions out of the cell during development.

Regulation of WNK1
The concentrations of Cl- ions and K+ ion play a major role in regulating WNK1 activity. In the DCT, the plasma concentration of K+ ion is thought to impact the concentration Cl- ions within the nephron. High plasma K+ concentration down regulates WNK1 activity and prevents Cl- ion from entering the nephron via the NCC. The opposite occurs when plasma K+ concentration is low; increased WNK1 activity boosts NCC activity promoting reabsorption of Cl- ions. When there is an abundance of Cl- ions within the nephron, WNK1 activity is inhibited by the binding of a Cl- ion to WNK1's catalytic domain.

Furthermore, WNK1 and WNK4 may interact to form heterodimers that inhibit WNK1 function. WNK4 release from the heterodimer allows WNK1 monomer to bind another WNK1 monomer to promote activation. WNK1 function can also be inhibited if WNK1 is degraded. There are two enzymes responsible for WNK1 ubiquitination, kelch like 3 (KLHL3) and cullin 3 (CUL3). KLHL3 serves as an adaptor protein that promotes the interaction between WNK1 and Cullin3, which is in a complex containing an E3 ubquitin ligase that attaches the ubiquitin molecules to WNK1. The ubiquitinated WNK1 will subsequently undergo proteasomal degradation.

Clinical significance[edit]
WNK1 has mutations associated with Gordon hyperkalemia-hypertension syndrome (pseudohypoaldosteronism Type II, featuring hypertension also called familial hyperkalemic hypertension (FHHt) )  and congenital sensory neuropathy (HSAN Type II, featuring loss of perception to pain, touch, and heat due to a loss of peripheral sensory nerves). See also: HSN2 gene.

Comparative genomics[edit]
The gene belongs to a group of four related protein kinases (WNK1, WNK2, WNK3, WNK4).

Homologs of this protein have been found in Arabidopsis thaliana, C. elegans, Chlamydomonas reinhardtii and Vitis viniferaas well as in vertebrates including Danio rerio and Taeniopygia guttata.

References[edit]

 * 1) ^ Jump up to:a b c